Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hemophilia
Pharma
Amid ongoing launches, Novo eyes rare disease leadership
As Novo advances its rare disease ambitions, the success of a hemophilia launch and late-stage sickle cell disease trial will be key.
Fraiser Kansteiner
Mar 7, 2025 9:20am
Pfizer empties gene therapy portfolio, discontinuing Beqvez
Feb 21, 2025 10:48am
Novo at last scores US green light for daily hemophilia med
Dec 23, 2024 10:33am
Novo Nordisk to build $1.2B rare disease drug factory in Denmark
Dec 16, 2024 10:26am
Europe's CHMP backs Novo's FDA-rejected hemophilia treatment
Oct 18, 2024 11:27am
FDA approves Pfizer's injected Hympavzi for hemophilia A or B
Oct 11, 2024 4:20pm
